Circadian Clock Proteins and Immunity|
Studies highlight the extent to which the molecular clock, most notably the core clock proteins BMAL1, CLOCK, and REV-ERBα, control fundamental aspects of the immune response. [Immunity]
HCV and HIV Co-Infection: Mechanisms and Management
New insights have revealed multiple mechanisms by which HCV and HIV lead to accelerated disease progression, specifically that HIV infection increases HCV replication, augments HCV-induced hepatic inflammation, increases hepatocyte apoptosis, increases microbial translocation from the gut and leads to an impairment of HCV-specific immune responses. [Nat Rev Gastroenterol Hepatol]
Chagas Disease: The Challenge of Polyparasitism?
Polyparasitism or mixed/concurrent infections occur more often than not and contribute to the high degree of variability observed across both disease progression and the success of therapeutic interventions. A thorough understanding of the effects of polyparasitism on Chagas disease (CD) is essential for improving the likelihood of containing, treating, and eventually eliminating CD. [Trends Parasitol]
Visit our reviews page to see a complete list of reviews in the infectious disease research field.
Unusual New HIV Drug Resistance Mechanism Revealed|
For the more than one million people with HIV/AIDS in the United States, antiretroviral drugs such as efavirenz and other so-called non-nucleoside reverse transcriptase inhibitors (NNRTIs) in combination with other antiretrovirals can be a lifeline, because they slow the progress of viral infection, prolonging life. Unfortunately, studies have shown that these benefits themselves can be short-lived in the clinic: therapy with NNRTIs can lead to single mutations in the HIV genetic code – mutations that make the virus resistant to the drugs. Researchers now have a good idea why. [Press release from Newswise Inc. discussing research presented at the 58th Annual Biophysical Society Meeting, San Francisco]
Press Release |
From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.
UNC Receives More than $40 million for Global Clinical Trials Unit to Treat, Prevent HIV|
The University of North Carolina at Chapel Hill has received a seven-year, more than $40 million award from the National Institutes of Health (NIH) for a clinical trials unit that will implement the scientific agendas of five NIH networks devoted to HIV/AIDS treatment, prevention and cure research. [The University of North Carolina at Chapel Hill]
Children’s Hospital Los Angeles Awarded $17 Million by NIH to Fund Clinical Research on HIV/AIDS
Grace Aldrovandi, MD, CM, principal investigator at The Saban Research Institute of Children’s Hospital Los Angeles, has been awarded $17 million by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH). The goal of this grant is to provide scientific leadership and infrastructure for laboratory testing as part of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network. [Business Wire]
Lupin Receives FDA Approval for Generic Mycobutin® Capsules
Pharma Major Lupin Limited (Lupin) announced that it has received final approval for its Rifabutin Capsules USP, 150 mg from the United States Food and Drugs Administration (FDA) to market a generic version of Pharmacia and Upjohn Company’s Mycobutin® Capsules 150 mg. [Pharma Major Lupin Limited]
Have we missed an important article or publication in Immunology of Infectious Disease News?
Click here to submit!
Comments or Suggestions? Submit your feedback here.